Researchers conducted a phase 2, 52-week double-blind dose-ranging study of once-daily semaglutide versus a placebo, with liraglutide 3 mg serving as an active control. Each participant also received dietary and exercise counseling.
Approximately 83 percent of semaglutide patients lost greater than or equal to 5 percent of their body weight, with 65 percent losing greater than or equal to 10 percent of their body weight.
The most common adverse events were dose-related gastrointestinal events, which are present when GLP-1 receptor agonists are used.
Novo Nordisk Chief Science Officer Mads Krogsgaard Thomsen said the company will pursue a phase 3 clinical development program in late 2018.
More articles on anesthesia:
10 things to know about Surgical Care Affiliates
New York health system eliminating outpatient surgery due to freestanding surgery center proliferation — 5 insights
Working capital as a percentage of ASC net revenue by region — 14 statistics
